Jul 14, 2026 07:32AM

Jul 14, 2026 07:30AM

Jul 9, 2026 07:30AM

Jul 9, 2026 07:30AM

Jul 6, 2026 07:30AM

Jul 6, 2026 07:30AM

Jun 18, 2026 07:00AM CervoMed receives U.S. patent for neflamapimod in pure DLB to 2042

Jun 18, 2026 07:00AM

Jun 16, 2026 03:22PM

Jun 16, 2026 10:18AM

Jun 10, 2026 07:30AM

Jun 10, 2026 07:30AM

May 18, 2026 07:30AM

Apr 22, 2026 07:30AM CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies

Apr 7, 2026 07:30AM

Apr 7, 2026 07:30AM

Mar 19, 2026 07:31AM

Mar 19, 2026 07:30AM

Mar 17, 2026 07:30AM

Mar 12, 2026 07:00AM

Mar 4, 2026 07:30AM CervoMed selects dosing for Phase 3 dementia with Lewy bodies trial

Mar 4, 2026 07:30AM

Feb 18, 2026 06:02AM

Feb 18, 2026 06:00AM

Dec 4, 2025 05:00PM

Dec 4, 2025 05:00PM

Dec 2, 2025 07:01AM

Dec 2, 2025 07:00AM CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

Nov 24, 2025 07:00AM

Nov 10, 2025 07:00AM

Nov 4, 2025 07:00AM

Nov 4, 2025 07:00AM

Oct 28, 2025 08:03AM

Oct 28, 2025 08:00AM

Oct 8, 2025 07:00AM CervoMed reports positive Phase 2b trial results for dementia drug

Oct 8, 2025 07:00AM

Oct 7, 2025 08:01AM

Oct 7, 2025 08:00AM

Sep 17, 2025 07:30AM

Aug 11, 2025 08:00AM

Jul 28, 2025 07:01AM

Jul 28, 2025 07:00AM CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated

Jun 10, 2025 08:00AM

May 12, 2025 08:00AM

Apr 2, 2025 07:00AM

Mar 17, 2025 08:00AM

Mar 10, 2025 04:05PM

Nov 12, 2024 07:00AM

Sep 18, 2024 05:17AM Chardan Capital Markets Starts CervoMed (CRVO) at Buy

Aug 12, 2024 08:00AM

1,168,703 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All